Biotechs are Expanding in the Bay Area Again: Bristol-Myers Squibb (BMY), Genentech (RHHBY), Gilead (GILD), Illumina (ILMN) and Verily and More
AstraZeneca PLC (AZN) Puts 'For Sale' Sign on U.S. HQ
Amidst Dramatic Reorganization, Takeda (TKPYY) May (Or May Not) Shutter Cambridge, UK Site
Embattled Theranos Plans to Appeal to Re-Open Its Lab in Newark, California
Mylan (MYL) Isn't Alone: 11 Drug Companies With Muscular Pricing Power and Staggering Profit Margins
What You Don't Know: Pfizer (PFE)’s Connection to Mylan (MYL) and EpiPen
Bay Area Life Sciences VC Firm Sofinnova Scores $595.5 Million
Alere (ALR) Drags Abbott (ABT) to Court to Force Completion of $5.8 Billion Deal
Merck & Co. (MRK)'s Keytruda May Have an Edge Over Bristol-Myers Squibb (BMY)'s Opdivo for Cancer Doctors
Adocia's Foot Ulcer Med Flunks Phase III Test
Novan Files Paperwork for $60 Million IPO to Develop Skin Drugs
Vanda (VNDA) Investors Elated Over Drug Patent Ruling
FDA Slaps Warning on Sun Pharma (SUNPHARMA.NS)'s Former U.S. Facility for Releasing Drug Despite Contamination Issues
These Biotech Employers Hired the Most New Grads In Life Sciences
Job Cuts Loom as Takeda (TKPYY) to Shutter Cambridge Office and Quits the UK
Facing Public Backlash and Pressure from Clinton, Mylan (MYL) Caves and Lowers Price of EpiPen
Medivation (MDVN) Exec Jumps Ship to Become CMO at BeiGene (BGNE)
Led by Former Genentech (RHHBY) Execs, Denali Banks $130 Million, Initiates Trial and Announces a Handful of Partnerships
See All News >
Job Cuts Loom as Takeda (TKPYY) to Shutter Cambridge Office and Quits the UK
Facing Public Backlash and Pressure from Clinton, Mylan (MYL) Caves and Lowers Price of EpiPen
Medivation (MDVN) Exec Jumps Ship to Become CMO at BeiGene (BGNE)
Led by Former Genentech (RHHBY) Execs, Denali Banks $130 Million, Initiates Trial and Announces a Handful of Partnerships
How Pfizer (PFE)’s Antibiotics Buy from AstraZeneca PLC (AZN) Will Affect Jobs in the U.S.
Best Places to Work in Life Sciences for LGBT Equality
Amgen (AMGN) Remains Hush-Hush Over FDA Rejection of Parsabiv
Just Days after a $14 Billion Medivation (MDVN) Buy, Pfizer (PFE) Buys AstraZeneca PLC (AZN)'s Antibiotics Business for $1.5 Billion-Plus
Teva (TEVA) Stock Plummets After Two Patents are Invalidated by Mylan (MYL)
Mylan (MYL) CEO Gets a 600% Pay Raise During Epipen's 400% Price Hike, Is She the Next Martin Shkreli?
Novartis AG (NVS) Touts Phase III Data for MS Drug Siponimod
3 High-Risk, High-Reward Biotech Stocks
Johnson & Johnson (JNJ) Might Become the First Company to Reach a $1 Trillion Valuation
McKesson (MCK) Slaps 'For Sale' Sign on San Francisco HQ With Plans to Lease Back a Portion of Building
Months After Infamous 'Sexist' Biotech Party, 20 Women Join New Exec Training
Turing CCO Claims Execs Retaliated After Shkreli’s Friend and Co-Founder Resigned Due to Sexual Assault Allegations
MIT Scientist Leonard Guarente Claims That This Pill Is the Fountain of Youth
Clovis Oncology (CLVS) Rockets as FDA Agrees to Priority Review of Rucaparib NDA
See All News >
//-->